Significant Ownership of Panacea Innovation Ltd
- Signature - Title
- /s/ James Huang - James Huang, Founding Managing Partner
- Location
- Grand Cayman, Cayman Islands
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Panacea Innovation Ltd.
Follow Filing Activity
Follow Panacea Innovation Ltd and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of Panacea Innovation Ltd
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Limited | Ordinary Shares | 25% | $13,950,000 | 13,950,000 | Panacea Innovation Limited | 21 Jul 2025 | ||
| CASI | CASI Pharmaceuticals, Inc. | Ordinary Shares | 22% | $4,698,042 | +$999,856 | 4,651,527 | +27% | James Huang | 16 Dec 2025 |
| CNTB | Connect Biopharma Holdings Limited | Ordinary Shares | 21% | $36,848,000 | +$3,248,000 | 13,160,000 | +9.7% | Panacea Innovation Limited | 31 Mar 2026 |
| ATRA | Atara Biotherapeutics, Inc. | Common Stock | 20% | -$1,154,619 | 1,632,345 | -4.7% | Panacea Innovation Limited | 12 Jan 2026 | |
| ATRA | Atara Biotherapeutics, Inc. | Common Stock | 16% | $6,449,392 | +$3,759,892 | 1,318,894 | +140% | Panacea Innovation Limited | 07 May 2026 |
| ADAG | Adagene Inc. | Ordinary Shares | 3.8% | $4,469,175 | -$1,564,211 | 2,250,000 | -26% | Panacea Venture Healthcare Fund II, L.P. | 30 Sep 2025 |
| AMLX | Amylyx Pharmaceuticals, Inc. | Common Stock, par value $0.0001 per share | 2.6% | $11,792,000 | 2,200,000 | Panacea Venture Healthcare Fund II, L.P. | 31 Dec 2024 | ||
| MRNS | Marinus Pharmaceuticals, Inc. | Common Stock | 0% | $0 | 0 | Panacea Venture Healthcare Fund II, L.P. | 31 Dec 2024 |
Schedules 13D/G Reported by Panacea Innovation Ltd:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.